Media Library

The Annual Report provides an overview of our strategy and reviews the performance of Novartis in 2017.

Our Annual Report 2018 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results.

MalaFA (Malaria Futures for Africa) is an opinion research study commissioned by Novartis to capture the views of African malaria experts in 15 sub-Saharan African countries – from government, the research community and NGOs – on progress and remaining challenges toward the 2030 global malaria goals. Study co-chairs are Dr Richard Kamwi, Ambassador, Elimination 8 (E8), and Professor Bob Snow, of the KEMRI-Wellcome Trust programme, Kenya and University of Oxford, United Kingdom.

Transparent reporting has been a central part of our CR commitment for many years, and we continue to make progress in this area. Our Novartis in Society Report (formerly the Corporate Responsibility Report) is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.

Our stakeholders have important questions about our business practices in the United States, including our approach to price adjustments, patient assistance, investment in research and development, and marketing. The Novartis in Society US report aims to help answer those questions.

Novartis Social Business (NSB) brings together the company’s key access-to-healthcare programs, including the Novartis Malaria Initiative, SMS for Life, Novartis Healthy Family, and Novartis Access. The 2018 NSB report provides a comprehensive overview of recent activities, and shows how these helps lower-income countries manage the dual burden of infectious and chronic diseases.

MalaFA (Malaria Futures for Asia) is an opinion research study commissioned by Novartis to capture the views of malaria experts in five countries in South and Southeast Asia – from government, the research community and NGOs – on progress and remaining challenges toward the 2030 malaria elimination goals. Study co-chairs are HE Yongyuth Yuthavong, former Deputy Prime Minister of Thailand and a member of the RBM Partnership to End Malaria board, and Dr Srinath Reddy, President of the Public Health Foundation of India.

Transparent reporting has been a central part of our CR commitment for many years, and we continue to make progress in this area. Our Novartis in Society Report is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.

The MalaFA CA (Malaria Futures for Central Africa supplementary report) is the latest extension of the Malaria Futures for Africa (MalaFA) study, commissioned by Novartis, which has already conducted similar research across 15 countries in Africa. The new supplementary report involved interviews with politicians, senior civil servants, malaria program directors, researchers and NGOs in Cameroon, Democratic Republic of the Congo (DRC), Republic of Congo, and Rwanda. All four are countries that have a significant malaria burden and differing policies in place to fight the disease. Study co-chairs are Dr Richard Kamwi, Ambassador, Elimination 8 (E8), and Professor Bob Snow, of the KEMRI-Wellcome Trust programme, Kenya and University of Oxford, United Kingdom.

Our stakeholders have important questions about our business practices in the United States, including our approach to price adjustments, patient assistance, investment in research and development, and marketing. The Novartis in Society US report aims to help answer those questions.

Our Annual Report 2019 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results.

This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements.